85-2059-77　［取扱停止］Enhanced FasL Pack, Soluble, Recombinant, Human, aa103-281 (Apoptosis Antigen Ligand, APT1LG1, APTL, CD95 Ligand, CD95L, CD95-L, FAS Antigen Ligand, Fas Ligand, CD178, FASLG, Tumor Necrosis Factor Ligand Superfamily Member 6, TNFSF6) 1 Set　207165

特徴

• FasL, soluble induces apoptosis in a concentration range of <1ng/ml in the presence of 0.1-1ug/ml of TNF Ligands Enhancer. Binds to human and mouse Fas (CD95; APO-1). Induces apoptosis of human Jurkat T cells at a concentration of <0.2ng/ml.
• Intended Use:Binds to human and mouse Fas (CD95; APO-1). Induces apoptosis of human Jurkat T cells at a concentration of <0.2ng/ml.
• Specificity:Human and mouse
• Source:Recombinant protein corresponding to aa103-281 from human FasL, fused to a FLAG®-tag at N-terminal, expressed in HEK 293 cells.
• Kit Components:FasL, Soluble, Recombinant, Human: 1x10ugTNF Ligands Enhancer: 4x50ug
• Concentration:FasL: 0.1mg/ml after reconstitutionTNF Ligands Enhancer: 1mg/ml after reconstitution
• Endotoxin Content:FasL: <0.05EU/ug (LAL test; Lonza)
• TNF Ligands Enhancer: <0.01EU/ug (LAL test; Lonza).
• Storage and Stability:Store powder at 4°C liquid at -20°C. Store other components at 4°C. Stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.